During a surgical process, doctors need many handpiece consumables ... and technical support for these machines. Alcon has the top market position in phacoemulsification (70% in the US and 50% ...

For instance, Alcon significantly boosted its R&D ... Additionally, disposable surgical instruments, such as single-use phacoemulsification handpieces, saw a 20% higher adoption rate in 2024 ...

GENEVA, Switzerland & ORLANDO, Fla., March 24, 2025--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR ...

Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a majority stake in the clinical-stage company and replacing its CEO.

Alcon, a leader in eye care, has shown solid performance since its 2019 spin-off, with strong growth prospects and strategic acquisitions enhancing its long-term outlook. The company reported ...

Please provide your email address to receive an email when new articles are posted on . Alcon will buy Lensar’s outstanding shares for $14 per share. The deal is expected to close in the second ...

Alcon to acquire LENSAR for $356 million to boost FLACS offering. The deal includes a $2.75 per share contingent milestone. Feel unsure about the market’s next move? Copy trade alerts from Matt ...

Swiss eyecare firm Alcon said on Monday it has agreed to a deal worth a potential $430 million with US counterpart Lensar, which offers advanced laser solutions for cataract treatments. In a joint ...

Eye care company Alcon Inc., which has a major presence in North Texas, plans to buy Lensar Inc. in a deal valued up to $430 million. Orlando-based Lensar (Nasdaq: LNSR) is a laser cataract ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed. Aurion will operate as ...

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control.